Bright Minds Biosciences Inc
DRUG82.120USD
-2.540-3.00%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
627.05MMarket Cap
LossP/E TTM
More Details of Bright Minds Biosciences Inc Company
Bright Minds Biosciences Inc. is a biotechnology company, which is engaged in developing treatments for patients with neurological and psychiatric disorders. The Company is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
Bright Minds Biosciences Inc Info
Ticker SymbolDRUG
Company nameBright Minds Biosciences Inc
IPO dateFeb 08, 2021
CEOMcdonald (Ian B)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 08
Address19 Vestry Street
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10013
Phone16478658622
Websitehttps://brightmindsbio.com/
Ticker SymbolDRUG
IPO dateFeb 08, 2021
CEOMcdonald (Ian B)
Company Executives of Bright Minds Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
20.61K
+347.15%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
5.00K
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Dr. Stephen D. Collins, M.D., Ph.D.
Dr. Stephen D. Collins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Ryan Cheung
Mr. Ryan Cheung
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jeremy Fryzuk
Mr. Jeremy Fryzuk
Independent Director
Independent Director
20.61K
+347.15%
Mr. Nils Christian Bottler
Mr. Nils Christian Bottler
Independent Director
Independent Director
5.00K
--
Dr. Jan Pedersen
Dr. Jan Pedersen
Chief Scientific Officer, Director
Chief Scientific Officer, Director
--
--
Dr. Stephen D. Collins, M.D., Ph.D.
Dr. Stephen D. Collins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David M. Weiner
Dr. David M. Weiner
Independent Director
Independent Director
--
--
Mr. Ian B. Mcdonald
Mr. Ian B. Mcdonald
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 25
Updated: Thu, Dec 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.71%
Cormorant Asset Management, LP
13.61%
McDonald (Ian)
12.91%
Vivo Capital, LLC
6.44%
Commodore Capital LP
6.42%
Other
45.91%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
14.71%
Cormorant Asset Management, LP
13.61%
McDonald (Ian)
12.91%
Vivo Capital, LLC
6.44%
Commodore Capital LP
6.42%
Other
45.91%
Shareholder Types
Shareholders
Proportion
Hedge Fund
39.54%
Investment Advisor/Hedge Fund
19.74%
Individual Investor
14.52%
Venture Capital
6.44%
Private Equity
5.77%
Investment Advisor
4.36%
Research Firm
2.84%
Pension Fund
0.10%
Bank and Trust
0.06%
Other
6.62%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
104
6.04M
75.19%
-130.00
2025Q3
104
6.04M
82.63%
+799.84K
2025Q2
92
5.24M
79.10%
+19.53K
2025Q1
56
5.22M
73.18%
+66.64K
2024Q4
44
4.90M
45.43%
+1.82M
2024Q3
24
191.55K
6.32%
-5.99K
2024Q2
26
197.54K
6.82%
-15.84K
2024Q1
26
213.38K
6.30%
-65.99K
2023Q4
25
228.36K
8.61%
+32.76K
2023Q3
25
195.60K
7.83%
+79.86K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
1.15M
16.17%
+34.29K
+3.09%
Jun 30, 2025
Cormorant Asset Management, LP
1.06M
14.95%
--
--
Jun 30, 2025
McDonald (Ian)
1.00M
14.18%
--
--
Feb 10, 2025
Vivo Capital, LLC
251.57K
3.55%
--
--
Jun 30, 2025
Commodore Capital LP
500.00K
7.06%
--
--
Jun 30, 2025
Perceptive Advisors LLC
420.69K
5.94%
-23.96K
-5.39%
Jun 30, 2025
Adage Capital Management, L.P.
200.00K
2.82%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
185.87K
2.62%
+185.35K
+35575.05%
Jun 30, 2025
Sio Capital Management, LLC
512.34K
7.23%
+4.78K
+0.94%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
4.93%
iShares Neuroscience and Healthcare ETF
0.8%
iShares Micro-Cap ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
AdvisorShares Psychedelics ETF
Proportion4.93%
iShares Neuroscience and Healthcare ETF
Proportion0.8%
iShares Micro-Cap ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.05%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
Date
Type
Ratio
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
Jun 22, 2023
Merger
5→1
FAQs
Who are the top five shareholders of Bright Minds Biosciences Inc?
The top five shareholders of Bright Minds Biosciences Inc are:
Janus Henderson Investors holds 1.15M shares, accounting for 16.17% of the total shares.
Cormorant Asset Management, LP holds 1.06M shares, accounting for 14.95% of the total shares.
McDonald (Ian) holds 1.00M shares, accounting for 14.18% of the total shares.
Vivo Capital, LLC holds 251.57K shares, accounting for 3.55% of the total shares.
Commodore Capital LP holds 500.00K shares, accounting for 7.06% of the total shares.
Janus Henderson Investors holds 1.15M shares, accounting for 16.17% of the total shares.
Cormorant Asset Management, LP holds 1.06M shares, accounting for 14.95% of the total shares.
McDonald (Ian) holds 1.00M shares, accounting for 14.18% of the total shares.
Vivo Capital, LLC holds 251.57K shares, accounting for 3.55% of the total shares.
Commodore Capital LP holds 500.00K shares, accounting for 7.06% of the total shares.
What are the top three shareholder types of Bright Minds Biosciences Inc?
The top three shareholder types of Bright Minds Biosciences Inc are:
Janus Henderson Investors
Cormorant Asset Management, LP
McDonald (Ian)
Janus Henderson Investors
Cormorant Asset Management, LP
McDonald (Ian)
How many institutions hold shares of Bright Minds Biosciences Inc (DRUG)?
As of 2025Q4, 104 institutions hold shares of Bright Minds Biosciences Inc, with a combined market value of approximately 6.04M, accounting for 75.19% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.45%.
What is the biggest source of revenue for Bright Minds Biosciences Inc?
In --, the -- business generated the highest revenue for Bright Minds Biosciences Inc, amounting to -- and accounting for --% of total revenue.
